MA38647B1 - Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x - Google Patents

Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x

Info

Publication number
MA38647B1
MA38647B1 MA38647A MA38647A MA38647B1 MA 38647 B1 MA38647 B1 MA 38647B1 MA 38647 A MA38647 A MA 38647A MA 38647 A MA38647 A MA 38647A MA 38647 B1 MA38647 B1 MA 38647B1
Authority
MA
Morocco
Prior art keywords
amino acid
receptor modulators
acid derivatives
conjugates
bile acid
Prior art date
Application number
MA38647A
Other languages
English (en)
Inventor
Roberto Pellicciari
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50721801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38647(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MA38647B1 publication Critical patent/MA38647B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un composé de formule (i) ou un sel, solvate ou conjugué d'acide aminé pharmaceutiquement acceptable de celui-ci, r
MA38647A 2013-05-14 2014-05-14 Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x MA38647B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361823169P 2013-05-14 2013-05-14
PCT/EP2014/059896 WO2014184271A1 (fr) 2013-05-14 2014-05-14 Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x

Publications (1)

Publication Number Publication Date
MA38647B1 true MA38647B1 (fr) 2019-05-31

Family

ID=50721801

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38647A MA38647B1 (fr) 2013-05-14 2014-05-14 Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x

Country Status (37)

Country Link
US (6) US9611289B2 (fr)
EP (4) EP3848038B1 (fr)
JP (2) JP6326131B2 (fr)
KR (1) KR102229952B1 (fr)
CN (2) CN108245523B (fr)
AU (1) AU2014267324B2 (fr)
BR (1) BR112015028399B1 (fr)
CA (1) CA2912139C (fr)
CL (2) CL2015003344A1 (fr)
CR (1) CR20150643A (fr)
CY (1) CY1122614T1 (fr)
DK (4) DK3360881T3 (fr)
EA (1) EA030152B1 (fr)
ES (4) ES2847002T3 (fr)
GT (1) GT201500324A (fr)
HK (2) HK1221471A1 (fr)
HR (1) HRP20180931T1 (fr)
HU (1) HUE037996T2 (fr)
IL (2) IL242555B (fr)
LT (1) LT2997035T (fr)
MA (1) MA38647B1 (fr)
ME (1) ME03082B (fr)
MX (1) MX352065B (fr)
MY (1) MY187886A (fr)
NI (1) NI201500160A (fr)
PE (1) PE20160665A1 (fr)
PH (1) PH12015502576A1 (fr)
PL (3) PL3360882T3 (fr)
PT (3) PT3360881T (fr)
RS (1) RS57372B1 (fr)
SA (1) SA515370140B1 (fr)
SG (1) SG11201509352XA (fr)
SI (3) SI3360881T1 (fr)
TN (1) TN2015000497A1 (fr)
TR (1) TR201809041T4 (fr)
UA (1) UA118673C2 (fr)
WO (1) WO2014184271A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157816A0 (en) 2001-03-12 2004-03-28 Roberto Pellicciari Steroids as agonists for fxr
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
ES2847002T3 (es) 2013-05-14 2021-07-30 Intercept Pharmaceuticals Inc Derivados 11-hidroxil-6-sustituidos de ácidos biliares y conjugados de aminoácido de los mismos como moduladores del receptor X farnesoide
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
JP6820253B2 (ja) * 2014-05-29 2021-01-27 バール ファーマシューティカルズ ソチエタ レスポンサビリタ リミタータ Ｆｘｂ及びｔｇｒ５／ｇｐｂａｒ１介在性疾患の治療及び／又は予防に使用するためのコラン誘導体
MX2017005935A (es) 2014-11-06 2018-01-11 Enanta Pharm Inc Análogos de ácido biliar como agonistas fxr/tgr5 y métodos de uso de los mismos.
KR102527821B1 (ko) 2014-11-19 2023-05-02 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
PL3221333T3 (pl) 2014-11-19 2020-01-31 NZP UK Limited Steroidy, 6.alfa-alkilo-3,7-diony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
EA033427B1 (ru) 2014-11-19 2019-10-31 Nzp Uk Ltd 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
CN107108687B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的5β-6-烷基-7-羟基-3-酮类固醇
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
MX2017006833A (es) 2014-11-26 2018-02-13 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
MA41094A (fr) * 2014-12-02 2017-10-10 Lilly Co Eli Procédés de traitement de troubles rénaux
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN104523703A (zh) * 2014-12-24 2015-04-22 聂飚 一种游离脂肪酸转运蛋白小分子抑制物的应用
ES2905872T3 (es) * 2015-02-06 2022-04-12 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia combinada
EP3256134A4 (fr) 2015-02-11 2018-10-03 Enanta Pharmaceuticals, Inc. Analogues de l'acide biliaire utilisés comme agonistes de fxr/tgr5 et leurs procédés d'utilisation
CN107530361A (zh) * 2015-03-09 2018-01-02 英特塞普特医药品公司 用于调节骨密度的方法
WO2016145216A1 (fr) * 2015-03-10 2016-09-15 Metselex, Inc. Acides biliaires fluorés et alkylés
JP2018510866A (ja) * 2015-03-13 2018-04-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腸受容体を活性化させるための、ファルネソイドｘ受容体アゴニストでの、成体の潜在性自己免疫性糖尿病の治療
SI3277286T1 (sl) 2015-03-31 2021-09-30 Enanta Pharmaceuticals, Inc. Derivati žolčne kisline kot antagonisti FXR/TGR5 in metode za njihovo uporabo
US10894054B2 (en) * 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
WO2016168553A1 (fr) * 2015-04-17 2016-10-20 Concert Pharmaceuticals, Inc. Acide obéticholique deutéré
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
CN106478759A (zh) * 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
WO2017053428A1 (fr) 2015-09-21 2017-03-30 Intercept Pharmaceuticals, Inc. Procédés pour favoriser la régénération hépatique
EP3981779A1 (fr) * 2015-10-07 2022-04-13 Intercept Pharmaceuticals, Inc. Modulateurs du récepteur farnésoïde x
WO2017147137A1 (fr) * 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Dérivés d'acide benzoïque d'acide biliaire utilisés en tant qu'agonistes de fxr/tgr5 et leurs méthodes d'utilisation
WO2017147174A1 (fr) * 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Analogues de l'acide biliaire contenant de l'hétéroaryle utilisés comme agonistes de fxr/tgr5 et leurs méthodes d'utilisation
WO2017147159A1 (fr) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Dérivés d'acide biliaire utilisés deutérés utilisés comme agonistes de fxr/tgr5 et leurs méthodes d'utilisation
EA038632B1 (ru) * 2016-03-11 2021-09-27 Интерсепт Фармасьютикалз, Инк. 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr)
IL262342B (en) * 2016-04-13 2022-08-01 Intercept Pharmaceuticals Inc fxr agonist for use as a drug for the treatment or prevention of hepatocellular carcinoma
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CA2968836A1 (fr) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Composes modulant fxr (nr1h4)
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
US10584145B2 (en) 2016-11-29 2020-03-10 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (fr) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Dérivés d'acide biliaire utilisés comme agonistes de fxr et leurs procédés d'utilisation
BR112019017312A2 (pt) 2017-02-21 2020-04-14 Genfit combinação de um agonista de ppar com um agonista de fxr
CN110461337A (zh) * 2017-02-23 2019-11-15 英特塞普特医药品公司 具有胆汁酸衍生物和微生物组的药物组合物及其用途
EP4424364A2 (fr) 2017-03-28 2024-09-04 Gilead Sciences, Inc. Méthodes de traitement d'une maladie hépatique
KR102624997B1 (ko) 2017-04-07 2024-01-12 이난타 파마슈티칼스, 인코포레이티드 술포닐 카바메이트 담즙산 유도체의 제조 방법
WO2018226724A1 (fr) * 2017-06-05 2018-12-13 Intercept Pharmaceuticals, Inc. Traitement et prévention de maladies oculaires diabétiques avec un dérivé d'acide biliaire
JP7224307B2 (ja) * 2017-06-23 2023-02-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁酸誘導体の調製のための方法及び中間体
MX2020000873A (es) 2017-07-24 2020-07-22 Intercept Pharmaceuticals Inc Derivados de ácidos biliares marcados isotópicamente.
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN109182451B (zh) * 2018-08-21 2021-06-11 四川大学 细胞色素cyp3a7酶的新型特异性探针反应及其应用
HUE065889T2 (hu) 2019-01-15 2024-06-28 Gilead Sciences Inc Izoxazol vegyület mint FXR agonista és az azt tartalmazó gyógyszerészeti készítmények
EP3927683A1 (fr) 2019-02-19 2021-12-29 Gilead Sciences, Inc. Formes solides d'agonistes de fxr
EP3976049A1 (fr) 2019-05-30 2022-04-06 Intercept Pharmaceuticals, Inc. Compositions pharmaceutiques comprenant un agoniste de fxr et un fibrate pour une utilisation dans le traitement d'une maladie hépatique cholestatique
WO2021009332A1 (fr) 2019-07-18 2021-01-21 Enyo Pharma Procédé pour diminuer les effets secondaires de l'interféron
CN110540955B (zh) * 2019-08-28 2021-09-17 北京协同创新研究院 一种提高分化细胞中nrob2基因表达量的方法
AU2021207253A1 (en) 2020-01-15 2022-06-09 Centre National De La Recherche Scientifique Use of FXR agonists for treating an infection by hepatitis D virus
AU2022209084A1 (en) 2021-01-14 2023-08-10 Centre Leon Bérard Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
EP4329761A1 (fr) 2021-04-28 2024-03-06 ENYO Pharma Potentialisation forte d'effets d'agonistes de tlr3 à l'aide d'agonistes de fxr en tant que traitement combiné
WO2022233398A1 (fr) * 2021-05-04 2022-11-10 Kostner Pharma Gmbh Composés pour réduire la lipoprotéine (a)
WO2023288123A1 (fr) 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Procédés et intermédiaires pour la préparation d'acide 3.alpha.,7.alpha.,11.bêta.-trihydroxy-6.alpha.-éthyl-5.bêta.-cholan-24-oïque

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2080775A (en) * 1934-08-22 1937-05-18 Celanese Corp Shedding mechanism for circular looms
US2802775A (en) * 1953-05-29 1957-08-13 Merck & Co Inc 11 alpha-hydroxylation of steroids by aspergillus ochraceus
JPS59205396A (ja) * 1983-05-09 1984-11-20 Kuraray Co Ltd １１β−ヒドロキシプレグナ−４−エン−３−オン−２０−カルブアルデヒド及びその製造法
US6639078B1 (en) 1998-12-23 2003-10-28 Smithkline Beecham Corporation Assays for ligands for nuclear receptors
ITMI20021532A1 (it) * 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
EP1568706A1 (fr) * 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Nouveau agonist steroidal pour FXR
DK1734970T3 (en) * 2004-03-12 2015-02-16 Intercept Pharmaceuticals Inc Treatment of fibrosis using FXR ligands
EP2040713B1 (fr) * 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Dérivés de l'acide biliaire en tant que des ligands de fxr pour la prévention ou le traitement de maladies ou conditions médiées par le fxr
ES2847002T3 (es) 2013-05-14 2021-07-30 Intercept Pharmaceuticals Inc Derivados 11-hidroxil-6-sustituidos de ácidos biliares y conjugados de aminoácido de los mismos como moduladores del receptor X farnesoide

Also Published As

Publication number Publication date
PT3360882T (pt) 2021-02-12
BR112015028399B1 (pt) 2021-11-16
CN108245523A (zh) 2018-07-06
CY1122614T1 (el) 2020-07-31
ES2671427T3 (es) 2018-06-06
PL2997035T3 (pl) 2018-10-31
UA118673C2 (uk) 2019-02-25
EP2997035A1 (fr) 2016-03-23
HK1221471A1 (zh) 2017-06-02
DK3360882T3 (da) 2021-03-08
US20140371190A1 (en) 2014-12-18
PT3360881T (pt) 2021-02-19
EP3848038B1 (fr) 2022-11-09
CL2015003344A1 (es) 2016-07-15
DK2997035T3 (en) 2018-07-02
US20170216316A1 (en) 2017-08-03
MY187886A (en) 2021-10-26
RS57372B1 (sr) 2018-08-31
CR20150643A (es) 2016-06-01
EP3848038A1 (fr) 2021-07-14
PL3360881T3 (pl) 2021-11-15
NI201500160A (es) 2016-01-04
HUE037996T2 (hu) 2018-09-28
EA201592055A1 (ru) 2016-11-30
IL242555A0 (en) 2016-02-01
PL3360882T3 (pl) 2021-10-25
JP2016518429A (ja) 2016-06-23
DK3360881T3 (da) 2021-03-15
EP3360882B1 (fr) 2020-12-09
AU2014267324A1 (en) 2015-11-26
ES2936638T3 (es) 2023-03-21
PT2997035T (pt) 2018-07-18
CN105377870B (zh) 2018-04-03
LT2997035T (lt) 2018-08-10
SI3360882T1 (sl) 2021-06-30
MX352065B (es) 2017-11-08
PH12015502576B1 (en) 2016-02-29
CN108245523B (zh) 2021-03-26
SI3360881T1 (sl) 2021-06-30
EP3360882A1 (fr) 2018-08-15
US20200297739A1 (en) 2020-09-24
CL2016001809A1 (es) 2017-01-27
KR102229952B1 (ko) 2021-03-22
NZ714082A (en) 2021-02-26
IL272718B (en) 2020-11-30
PE20160665A1 (es) 2016-08-07
EP3360881A1 (fr) 2018-08-15
CN105377870A (zh) 2016-03-02
TR201809041T4 (tr) 2018-07-23
EP3360881B1 (fr) 2020-12-09
IL242555B (en) 2020-04-30
SA515370140B1 (ar) 2017-04-11
DK3848038T3 (da) 2023-02-06
US20190209586A1 (en) 2019-07-11
GT201500324A (es) 2017-09-28
CA2912139C (fr) 2021-04-20
AU2014267324B2 (en) 2017-11-02
ES2843737T3 (es) 2021-07-20
KR20160007586A (ko) 2016-01-20
ES2847002T3 (es) 2021-07-30
JP6326131B2 (ja) 2018-05-16
US20230233581A1 (en) 2023-07-27
US10532061B2 (en) 2020-01-14
PH12015502576A1 (en) 2016-02-29
IL272718A (en) 2020-04-30
US20210228599A1 (en) 2021-07-29
US11000532B2 (en) 2021-05-11
US9611289B2 (en) 2017-04-04
BR112015028399A2 (pt) 2017-07-25
JP2018127481A (ja) 2018-08-16
ME03082B (fr) 2019-01-20
EP2997035B1 (fr) 2018-03-28
EP2997035B8 (fr) 2018-05-23
WO2014184271A1 (fr) 2014-11-20
SI2997035T1 (sl) 2018-10-30
EA030152B1 (ru) 2018-06-29
HK1253326A1 (zh) 2019-06-14
CA2912139A1 (fr) 2014-11-20
HRP20180931T1 (hr) 2018-10-05
TN2015000497A1 (en) 2017-04-06
SG11201509352XA (en) 2015-12-30

Similar Documents

Publication Publication Date Title
MA38647B1 (fr) Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x
CY1124404T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA38922A3 (fr) Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
PH12018500777A1 (en) Farnesoid x receptor modulators
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
ECSP12012290A (es) Formulaciones farmacéuticas
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
EA201101026A1 (ru) Ингибиторы бета-секретазы
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201071329A1 (ru) Диамидные производные адамантана и их применение
MA38583B1 (fr) Dérivés de dolastatine 10 et d'auristatines
BR112014026266A2 (pt) derivado de quinazolidinadiona
BRPI1014802B8 (pt) profármacos de triptolida.
MA41337A (fr) Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
CY1125355T1 (el) Πεντακυκλικη ενωση